TME Pharma

TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned. 

SNO 2023 poster: Lastest data in Glioblastoma from the expansion arm with NOX-A12 + radiotherapy + anti-VEGF

Fact SheetCorporate PresentationCEO Message H1 2024

Press Release 2024, August 27 06:00 p.m. TME Pharma announces convocation of an extraordinary general meeting of shareholders 2024, August 12 07:00 p.m. TME Pharma provides update on resources allocated to the liquidity contract with Invest Securities 2024, July 31 06:00 p.m. Half-yearly report on the liquidity contract with Invest Securities

Events ESMO Congress 2024 September 13 - 17 | Barcelona, Spain Mini Oral Presentation: Spatial remodeling of the immune tumor microenvironment after radiotherapy and CXCL12 inhibition in glioblastoma in the phase 1/2 GLORIA trial Dr. Frank Giordano, University Medical Center, Mannheim September 15 | 08.30-08.35 am CEST Health Tech Innovation Days (HTID Conference) Aram Mangasarian September 17-18 | Paris, France 24th Annual Biotech in Europe Forum Aram Mangasarian, Ewelina Staniuk September 25-26 | Basel, Switzerland BIO-Europe Dirk Eulberg, Ewelina Staniuk November 4 -6 | Stockholm, Sweden TIDES Europe Aram Mangasarian, Stefan Vonhoff November 12 - 14 | Hamburg, Germany Latest Analyst Report Invest Securities Jamila El Bougrini, PhD 2024, July 18 (EN/FR)